SEI Form 4: Director granted 6,052 RSAs and sold 10,000 shares at $28.86
Rhea-AI Filing Summary
Edgar R. Giesinger Jr., a director of Solaris Energy Infrastructure, Inc., reported two trades in Class A common stock. On 08/23/2025 he was granted 6,052 restricted shares under the company’s Long Term Incentive Plan; those restricted shares vest in full on the first anniversary of the grant date. Two days later, on 08/25/2025, the reporting person sold 10,000 shares at a weighted-average price of $28.86 per share (sales occurred at prices ranging from $28.67 to $29.19). Following the transactions the filing shows the reporting person beneficially owned 90,956 shares. The Form 4 was signed by an attorney-in-fact on 08/26/2025 and includes a statement that the reporting person will provide detailed per-trade pricing on request.
Positive
- 6,052 restricted shares granted under the Long Term Incentive Plan that vest in full one year after grant, aligning director incentives with shareholders
- Full disclosure of sale pricing range and an offer to provide per‑trade details on request, supporting transparency
Negative
- 10,000 shares sold on 08/25/2025, reducing beneficial ownership to 90,956 shares
- No indication in the filing that the sale was made pursuant to a 10b5‑1 plan (the 10b5‑1 box is not checked)
Insights
TL;DR: Director received time‑based equity and completed a small open‑market sale, resulting in modest net reduction in holdings.
The grant of 6,052 restricted shares aligns the director’s compensation with shareholder value over the next year because the award vests in full on the first anniversary. The subsequent sale of 10,000 shares at a weighted average of $28.86 reduced beneficial holdings to 90,956 shares. The transactions are routine: an award under the LTIP and an open‑market disposition with disclosed price range. No derivative transactions or other material changes were reported.
TL;DR: Governance signals are standard: time‑based equity grant plus an opportunistic share sale; disclosures appear complete.
The Form 4 discloses the nature of the restricted stock award and the vesting schedule, meeting typical transparency expectations. The sale was reported with a weighted average price and a footnote offering full per‑trade pricing upon request, which supports compliance. There is no indication of transactions under a 10b5‑1 plan or other contingent arrangements in the filing.